Mutations and/or differential expression of microglial specific receptors such as TREM2, CD33, and CR3 have been associated with strong increased risk for developing Alzheimer’s disease (AD). This evidence concerns the gene CD33 and early-onset autosomal dominant Alzheimer disease.